Princess Alexandra Research Foundation awards for APCRC-Q Researchers
Dr Hollier received a Translational Research Innovation Award for his project entitled: The translation of a novel targeted agent in the treatment of neuroendocrine prostate cancer. The grant is valued at $100,000 for one year.
“This project focusses on testing a new targeted agent to treat advanced forms of prostate cancer, which are resistant to current androgen-targeted therapies,” said Dr Hollier, “We greatly appreciate the financial support from the PA Research Foundation that will make this important research possible.”
A/Prof Elizabeth Williams and her transdisciplinary team of clinicians and researchers (Dr Ian Vela, DProf Dietmar Hutmacher, Dr Ben Shepherd, Prof Matt Brown, Dr Nathalie Bock, and Dr Saeid Alinezhad) also received a Translational Research Innovation Award of $100,000 for one year for their project entitled: “A multifaceted precision approach to high risk prostate cancer”.
“We are delighted to receive this award, which will fund our project to assess feasibility and efficacy of a translational “precision” approach to men with high risk prostate cancer in order to direct future therapeutic decisions,” said A/Prof Elizabeth Williams.
“By examining tissue from prostate cancer tumours of men with high risk disease we hope to identify effective therapy strategies to guide physicians in their choice of treatment to avoid those treatment regimens to which the cancer shows intrinsic resistance and to help patients avoid therapies which will inevitably not yield results.”
